Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P54252
UPID:
ATX3_HUMAN
Alternative names:
Machado-Joseph disease protein 1; Spinocerebellar ataxia type 3 protein
Alternative UPACC:
P54252; A7LFZ5; D6RDL9; E9PB63; O15284; O15285; O15286; Q8N189; Q96TC3; Q96TC4; Q9H3N0
Background:
Ataxin-3, known as Machado-Joseph disease protein 1 or Spinocerebellar ataxia type 3 protein, plays a crucial role in protein homeostasis, transcription regulation, and autophagy. It functions by binding and trimming long polyubiquitin chains, and is involved in the degradation of misfolded chaperone substrates through its interaction with STUB1/CHIP.
Therapeutic significance:
Spinocerebellar ataxia 3, a disorder characterized by progressive incoordination and cerebellum degeneration, is directly linked to mutations in the Ataxin-3 gene. Understanding the role of Ataxin-3 could open doors to potential therapeutic strategies for this and related neurodegenerative diseases.